Bioprosthetic vs mechanical mitral valve replacement for infective endocarditis in patients aged 50 to 69 years
© 2020 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc..
BACKGROUND: The optimal choice of the valve prosthesis in mitral valve replacement (MVR) for infective endocarditis (IE) is controversial and challenging, particularly for younger patients.
HYPOTHESIS: The postoperative outcomes of mechanical and biological MVR in IE patients aged 50 to 69 years are different.
METHODS: All IE patients aged 50 to 69 years with primary MVR in Hubei province hospitals from 2002 to 2018 were retrospectively reviewed. The median duration of follow-up was 8.7 years (IQR, 6.8-10.9 years). Propensity score matching (1:3 ratio) was used to yield 492 patients with comparable baseline features between bioprostheses and mechanical prosthetic valve groups. Outcomes were postoperative mid- to long- term survival, mitral valve reoperation, prosthetic valve endocarditis (PVE), stroke, and major bleeding events.
RESULTS: Fifteen-year survival after MVR was 80.6% in the mechanical valve group and 69.3% in the bioprostheses group (HR 0.545, P = .040). The cumulative incidence of mitral valve reoperation was 8.8% with mechanical valves and 21.4% with bioprostheses (HR 0.260, P = .002). The cumulative incidence of PVE was 5.6% with mechanical valves and 7.2% with bioprostheses (HR 0.629, P = .435). The cumulative incidence of stroke was 12.9% with mechanical valves and 10.5% with bioprostheses (HR 1.217, P = .647). The cumulative incidence of major bleeding was 12.0% with mechanical valves and 6.75% with bioprostheses (HR 1.579, P = .268).
CONCLUSIONS: Mechanical valve prostheses were associated with better survival, lower rates of reoperation compared with bioprostheses within 15 years after MVR in IE patients aged 50 to 69. These findings suggest mechanical valve prostheses may be a more reasonable alternative to bioprostheses in this patient group.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Clinical cardiology - 43(2020), 10 vom: 06. Okt., Seite 1093-1099 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hu, Xingjian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bioprosthesis |
|---|
| Anmerkungen: |
Date Completed 10.08.2021 Date Revised 10.08.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/clc.23407 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31076923X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31076923X | ||
| 003 | DE-627 | ||
| 005 | 20231225140814.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/clc.23407 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1035.xml |
| 035 | |a (DE-627)NLM31076923X | ||
| 035 | |a (NLM)32497339 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hu, Xingjian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bioprosthetic vs mechanical mitral valve replacement for infective endocarditis in patients aged 50 to 69 years |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.08.2021 | ||
| 500 | |a Date Revised 10.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc. | ||
| 520 | |a BACKGROUND: The optimal choice of the valve prosthesis in mitral valve replacement (MVR) for infective endocarditis (IE) is controversial and challenging, particularly for younger patients | ||
| 520 | |a HYPOTHESIS: The postoperative outcomes of mechanical and biological MVR in IE patients aged 50 to 69 years are different | ||
| 520 | |a METHODS: All IE patients aged 50 to 69 years with primary MVR in Hubei province hospitals from 2002 to 2018 were retrospectively reviewed. The median duration of follow-up was 8.7 years (IQR, 6.8-10.9 years). Propensity score matching (1:3 ratio) was used to yield 492 patients with comparable baseline features between bioprostheses and mechanical prosthetic valve groups. Outcomes were postoperative mid- to long- term survival, mitral valve reoperation, prosthetic valve endocarditis (PVE), stroke, and major bleeding events | ||
| 520 | |a RESULTS: Fifteen-year survival after MVR was 80.6% in the mechanical valve group and 69.3% in the bioprostheses group (HR 0.545, P = .040). The cumulative incidence of mitral valve reoperation was 8.8% with mechanical valves and 21.4% with bioprostheses (HR 0.260, P = .002). The cumulative incidence of PVE was 5.6% with mechanical valves and 7.2% with bioprostheses (HR 0.629, P = .435). The cumulative incidence of stroke was 12.9% with mechanical valves and 10.5% with bioprostheses (HR 1.217, P = .647). The cumulative incidence of major bleeding was 12.0% with mechanical valves and 6.75% with bioprostheses (HR 1.579, P = .268) | ||
| 520 | |a CONCLUSIONS: Mechanical valve prostheses were associated with better survival, lower rates of reoperation compared with bioprostheses within 15 years after MVR in IE patients aged 50 to 69. These findings suggest mechanical valve prostheses may be a more reasonable alternative to bioprostheses in this patient group | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a bioprosthesis | |
| 650 | 4 | |a endocarditis | |
| 650 | 4 | |a long-term outcome | |
| 650 | 4 | |a mechanical valve | |
| 650 | 4 | |a mitral valve replacement | |
| 700 | 1 | |a Jiang, Weiwei |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Minghui |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Ruikang |e verfasserin |4 aut | |
| 700 | 1 | |a Yim, Wai Yen |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Nianguo |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cardiology |d 1992 |g 43(2020), 10 vom: 06. Okt., Seite 1093-1099 |w (DE-627)NLM000419834 |x 1932-8737 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2020 |g number:10 |g day:06 |g month:10 |g pages:1093-1099 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/clc.23407 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2020 |e 10 |b 06 |c 10 |h 1093-1099 | ||